evidence table
Berberine Lipids Meta-Analysis Evidence Table
Structured evidence table for Berberine Lipids Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Berberine Lipids Meta-Analysis | As such, it may be beneficial to use berberine combined with statins in people with hyperlipidemia, especially for those with statin intolerance or partial intolerance, and those with diabetes or at high risk of diabetes. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Lipids Meta-Analysis | Berberine has been recommended by the International Lipid Expert Panel and the 2019 European Atherosclerosis Society/European Society of Cardiology Guidelines for the treatment of hyperlipidemia in statin-intolerant patients, however, these guidelines have not provided explicit recommendations about the use of berberine because of the lack of high-quality evidence. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Lipids Meta-Analysis | Despite of the benefits on lipid profile and glucose metabolism, the effect of berberine on the risk of IHD and diabetes has not been clarified. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Lipids Meta-Analysis | 1 2 3 4 Ischemic heart disease (IHD) is the single leading cause of mortality and poses a heavy burden on healthcare, which accounts for ~16% of all deaths globally. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Lipids Meta-Analysis | Dysregulated adipogenesis in obesity involves excessive preadipocyte recruitment and differentiation, leading to increased adipocyte number (hyperplasia) and hypertrophy. | 3 | Marie Ohoud M. (2026) | Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions |
| Berberine Lipids Meta-Analysis | In obesity, lipolytic capacity is suppressed through multiple mechanisms including impaired sympathetic nervous system signaling and reduced expression of lipolytic enzymes (Thorp and Schlaich ). | 3 | Marie Ohoud M. (2026) | Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions |
| Berberine Lipids Meta-Analysis | At the molecular level, obesity‐associated chronic inflammation and elevated circulating free fatty acids impair leptin signaling through the hypothalamic leptin receptor (Jais and Brüning ). | 3 | Marie Ohoud M. (2026) | Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions |
| Berberine Lipids Meta-Analysis | 2025 2025 2025 2025 2023 Obesity represents one of the most pressing public health challenges of the 21st century, characterized by excessive accumulation of adipose tissue that impairs health and quality of life (Ahmed and Mohammed ; Lewandowska et al. ). | 3 | Marie Ohoud M. (2026) | Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions |
Source documents